Lonza has announced that CEO Wolfgang Wienand will present at the Jefferies Global Healthcare Conference in London on 18 November 2026, with the session scheduled from 15:30 to 15:55 GMT. The presentation will be followed by a question-and-answer session, and the event will be webcast live, according to a company release distributed via NEWMEDIAWIRE.
The announcement matters because it gives investors and analysts direct access to management at a time when Lonza is positioning itself as the world’s leading contract development and manufacturing organization. The company works with pharmaceutical and biotech partners across three continents to turn breakthrough innovations into viable therapies, and the conference provides a platform to discuss strategy, performance and market outlook.
A live audio webcast will be available through a dedicated link, and a replay will remain accessible for 90 days on Lonza’s Investor Relations website. That extended access is significant for shareholders who cannot tune in live, and it reflects the company’s effort to maintain transparent communication with the investment community.
Lonza’s scale underscores why its conference appearances draw attention. The company employs approximately 17,000 colleagues and generated sales of CHF 3.4 billion with a CORE EBITDA of CHF 1.2 billion in Half-Year 2026. Those figures highlight the financial weight of the CDMO sector and the role Lonza plays in supplying manufacturing capacity and expertise to the healthcare industry. More information about the company is available at www.lonza.com.
For investors, the Jefferies conference is one of several opportunities to assess how Lonza is navigating demand for outsourced development and manufacturing. The CEO’s remarks could shed light on capacity utilization, customer trends and the integration of cutting-edge science and lean manufacturing across the company’s global network.
Lonza Group Ltd is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange, with a secondary listing on the Singapore Exchange Securities Trading Limited. The company’s participation in a major healthcare conference also signals its continued engagement with the global investment community as it supports pharma and biotech customers in bringing life-saving and life-enhancing treatments to patients worldwide.
The original release is available on www.newmediawire.com.


